Back to News
Market Impact: 0.15
SELLAS Phase 3 REGAL AML Trial Of Galinpepimut-S Reaches Final Analysis Trigger
Source: Nasdaq
Healthcare & Biotech
SELLAS Life Sciences announced an update concerning its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The supplied article text cuts off before specifying the update or any trial results, so no outcome or market reaction is reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Aspen Neuroscience prices IPO at $15 per share
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share on Nasdaq